SoFi Technologies (SOFI) Today — Nov. 7, 2025: Shares Ease After Big Run as Fresh Analyst Takes, New Forecasts and “Risk Reduction” Move Make Headlines
7 November 2025
2 mins read

SoFi Technologies (SOFI) Today — Nov. 7, 2025: Shares Ease After Big Run as Fresh Analyst Takes, New Forecasts and “Risk Reduction” Move Make Headlines

SoFi Technologies, Inc. (NASDAQ: SOFI) is trading lower in Friday action after a powerful multi‑week rally, with new same‑day coverage highlighting a short‑term pullback, mixed Wall Street views, and commentary that the company is “reducing risk” in its model—an investor‑friendly shift if sustained. As of ~14:50 UTC, shares were changing hands around $26.38 (about ‑2.9% intraday).

What’s new today (Nov. 7, 2025)

  • Motley Fool/Nasdaq: A Friday morning take argues SoFi is taking steps to reduce risk in the business, a positive for shareholders. While framed as analysis, it underscores the company’s ongoing shift toward more capital‑light revenue streams. 1
  • TipRanks: Coverage notes Thursday’s ~10% pullback following a big run and a Hold consensus across Wall Street, with an average price target near $27.21. The same write‑up cites Jefferies lifting its target to $35 (Buy) and KBW maintaining Sell with a $20 target—illustrating a wide dispersion of views. 2
  • 24/7 Wall St.: A forecast piece published this morning pegs the one‑year Street consensus at ~$26.03 and lists 6 Buy recommendations out of 22 analysts, while the outlet’s own near‑term target is $29.41. Treat these as opinions/estimates rather than facts, but they add useful context on expectations vs. price. 3
  • Market color: Independent market commentary describes today’s dip as a “healthy correction” after the surge into quarter‑end, emphasizing SoFi’s growth story even as the stock cools. This is sentiment‑driven (not an official company update). 4

Why Friday’s headlines matter

  1. Model mix keeps shifting toward “capital‑light.”
    The risk‑reduction narrative aligns with SoFi’s multi‑year push beyond balance‑sheet lending into fee and platform revenue. That direction was front‑and‑center in last week’s results and helps frame why commentary today is applauding a lower‑risk posture. 1
  2. Street is still split—even after a blowout quarter.
    Fresh pieces this morning again highlight the consensus “Hold” and spread of targets ($20 on the low end, $35 on the high end). Divergent views typically mean news flow and execution can move the stock swiftly. 2
  3. Price vs. target tension.
    With shares hovering around the mid‑$20s, several same‑day rundowns note the average near‑term target sits around where the stock trades (or slightly below), while some analysts and outlets see more headroom. That tug‑of‑war often defines near‑term trading ranges. 3

Quick refresher: the results powering the rally

  • Q3 2025: SoFi reported record net revenue of ~$962M, adjusted net revenue of ~$950M, net income of ~$139M, and adjusted EPS of $0.11, with 905k new members and 18.6M total products—and raised full‑year 2025 guidance (including EPS to ~$0.37). These numbers, released Oct. 28, set the tone for the recent advance. 5

Analyst and target snapshot (as highlighted today)

  • Consensus:Hold, average target ≈ $27.21 (TipRanks).
  • Examples called out today:Jefferies $35 (Buy); KBW $20 (Sell)—illustrating how opinions still range widely even after the Q3 beat/raise. 2
  • Independent forecast (media): 24/7 Wall St. cites a Street one‑year target of $26.03 and offers its own $29.41 year‑end figure; again, that’s a media projection, not company guidance. 3

Near‑term catalyst to watch

  • Investor appearance: SoFi lists participation in the KBW Fintech Payments Conference on Nov. 11, 2025 (webcast)—an opportunity for management to reinforce the capital‑light strategy and field questions on credit, deposits, and growth initiatives. 6

Key takeaways for Nov. 7

  • Stock action:SOFI is off ~2.9% intraday after a strong run, consolidating around the mid‑$20s. (See live chart above.)
  • News tone: Today’s coverage blends risk‑reduction commentary with balanced Street sentiment and fresh forecasting pieces. 1
  • Backdrop: Last week’s record quarter + guidance raise remain the fundamental driver behind 2025’s momentum. 5

Not investment advice. Markets involve risk, including loss of principal. Always do your own research and consider consulting a licensed advisor.

A technology and finance expert writing for TS2.tech. He analyzes developments in satellites, telecommunications, and artificial intelligence, with a focus on their impact on global markets. Author of industry reports and market commentary, often cited in tech and business media. Passionate about innovation and the digital economy.

Stock Market Today

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

7 February 2026
MARA shares jumped 22.4% to $8.24 Friday, trading higher after hours, as the company moved $87 million in bitcoin to major custodians. About 82.4 million MARA shares changed hands. Bitcoin hovered near $68,928 Saturday. A MARA filing showed its general counsel had shares withheld for taxes on vested stock units, not an open market sale.
Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

7 February 2026
Apple shares closed up 0.8% at $278.12 Friday, then slipped 0.3% after hours. A global DRAM shortage is raising component costs, putting pressure on Apple’s pricing ahead of its Feb. 24 shareholder meeting. CEO Tim Cook said memory prices will rise “sharply” but gave no details on possible iPhone price hikes. Investors await signals before next week’s U.S. inflation data.
Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

7 February 2026
Roivant shares surged 22.4% to $25.82 after Phase 2 data showed its drug brepocitinib outperformed placebo in cutaneous sarcoidosis, with no serious adverse events. The company plans a Phase 3 trial in 2026 and has filed for FDA approval in dermatomyositis. Quarterly revenue reached $2 million, with a $313.7 million loss. Cash holdings stood at $4.5 billion.
NIO (NIO) Today: Firefly EVs Set Sail for Europe, Austria Launch Goes Live, North America on the Map as Shares Hover Near $6.90
Previous Story

NIO (NIO) Today: Firefly EVs Set Sail for Europe, Austria Launch Goes Live, North America on the Map as Shares Hover Near $6.90

AMD Today: 2nm ‘Venice’ CPUs & MI400 AI Accelerators Confirmed for 2026 as Shares Flicker Ahead of Nov. 11 Analyst Day
Next Story

AMD Today: 2nm ‘Venice’ CPUs & MI400 AI Accelerators Confirmed for 2026 as Shares Flicker Ahead of Nov. 11 Analyst Day

Go toTop